[
  {
    "ts": null,
    "headline": "The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter",
    "summary": "Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more on LLY and NVO stocks here.",
    "url": "https://finnhub.io/api/news?id=3523e47bdfa2d6d55df6af8c745a7269fd0047475305b58f18e171b855eabe97",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757745000,
      "headline": "The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter",
      "id": 136733182,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1388387575/image_1388387575.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more on LLY and NVO stocks here.",
      "url": "https://finnhub.io/api/news?id=3523e47bdfa2d6d55df6af8c745a7269fd0047475305b58f18e171b855eabe97"
    }
  }
]